Zevra Therapeutics (ZVRA) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Zevra’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Restructures to Focus on Rare Diseases
- Zevra Therapeutics announces departure of CDO Christal Mickle, CSO Sven Guenther
- Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease
- Zevra Therapeutics announces U.S. commercial availability of MIPLYFFA
- Zevra Therapeutics price target lowered to $23 from $25 at Canaccord
Questions or Comments about the article? Write to editor@tipranks.com